Arcus Biosciences holders back board and pay
Arcus Biosciences, Inc. held its annual meeting of stockholders on June 11, 2026, where all management proposals were approved.
Rhea-AI Filing Summary
Arcus Biosciences, Inc. held its annual meeting of stockholders on June 11, 2026, where all management proposals were approved. Stockholders elected four Class II directors—Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier—to serve until the 2029 annual meeting and until their successors are duly elected and qualified.
Shareholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Nicole Lambert: 92,653,341 votes
Votes for Dietmar Berger: 85,949,508 votes
Auditor ratification votes for: 112,905,582 votes
+4 more
7 metrics
Votes for Nicole Lambert
92,653,341 votes
Election as Class II director at 2026 annual meeting
Votes for Dietmar Berger
85,949,508 votes
Election as Class II director at 2026 annual meeting
Auditor ratification votes for
112,905,582 votes
Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Auditor ratification votes against
4,767,430 votes
Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Say-on-pay votes for
94,920,421 votes
Advisory approval of named executive officer compensation
Say-on-pay votes against
9,337,368 votes
Advisory approval of named executive officer compensation
Broker non-votes
13,573,227 votes
Applied to director elections and say-on-pay proposal
Key Terms
broker non-votes, independent registered public accounting firm, advisory basis, emerging growth company, +1 more
5 terms
broker non-votes financial
"Votes For | Votes Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ernst & Young LLP as the independent registered public accounting firm of the Company"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory basis financial
"The approval, on an advisory basis, of the compensation of the Company's named executive officers"
emerging growth company regulatory
"Emerging growth company o"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
annual meeting of stockholders financial
"held its annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Arcus Biosciences (RCUS) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing four Class II directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving executive compensation on an advisory basis. All three proposals received sufficient support to pass at the June 11, 2026 annual meeting.
Were Arcus Biosciences (RCUS) director nominees elected at the 2026 annual meeting?
Yes. All four Class II director nominees—Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier—were elected to serve until the 2029 annual meeting. Each nominee received more votes for than withheld, with additional broker non-votes recorded for each seat.
Did Arcus Biosciences (RCUS) stockholders ratify Ernst & Young as auditor for 2026?
Yes. Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 112,905,582 votes for, 4,767,430 votes against, and 187,745 abstentions recorded in the tally.
What are broker non-votes in the Arcus Biosciences (RCUS) 2026 vote results?
Broker non-votes occur when brokers do not have discretionary authority to vote on a proposal and receive no voting instructions from beneficial owners. For the director elections and say-on-pay proposal, Arcus recorded 13,573,227 broker non-votes, which did not prevent those items from passing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
